The Global Health Body Raises Warning Over Critical Lack of Weight-Loss Injections
Under one in 10 people who could benefit from weight-loss injections including Wegovy have access to them, caution the global health agency as it publishes its inaugural advice on the drugs.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for increased and just access to GLP-1 medication.
Per projections, more than two billion are projected to be living with obesity by 2030 without intervention.
"The new guidance affirms that excess weight is a long-term condition that can be addressed with thorough and lifelong support," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are key hurdles to broad availability to the treatments that can assist patients in reducing substantial weight, explains the organization.
Weight-Loss Drug Shortage
Even in the present most optimistic outlook, the manufacturing of such drugs would only suffice for approximately 100 million people – less than 10% of those who need them, as stated by the WHO.
The recommendation urges governments and firms to widen access, through strategies including licensing agreements.
The intellectual property rights on a key compound – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs mimick a natural hormone to slow digestion, suppress the appetite and boost the sense of being full so individuals reduce food intake.
People commonly see weight reduction after several weeks of starting on the once-weekly jabs.
Evidence points to users may put most of the weight back on a year later of stopping the treatment, because their usual hunger return.
To be overweight or obese raises your likelihood for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns people in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
